TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03384316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
Study: NCT02610231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg or 40 mg
Description: Istradefylline 20 or 40 mg
Study: NCT03034746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Description: It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive treatment (CT)
Description: The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
Study: NCT01389895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 557 Placebo
Description: AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Study: NCT03315338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 100mg
Description: CORT118335 is supplied as a suspension for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 300mg
Description: CORT118335 is supplied as a suspension for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 900mg
Description: CORT118335 is supplied as a suspension for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 900mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study: NCT01233739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 capsules of placebo orally.
Study: NCT04445597

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of tissue
Description: In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
Study: NCT03315338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 150mg
Description: CORT118335 is supplied as a suspension for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 1500mg
Description: CORT118335 is supplied as a suspension for oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered
Study: NCT03691350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02929901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine and chlorogenic acid
Description: caffeine plus chlorogenic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: caffeine plus placebo
Study: NCT00013091

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management therapy; Psychoeducational group therapy
Study: NCT02929901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chlorogenic acid
Description: chlorogenic acid plus placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo plus placebo
Study: NCT02516826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Study: NCT03502434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study: NCT03315338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered
Study: NCT02516826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination
Description: Rosuvastatin/Olmesartan(Combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan
Study: NCT02516826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin/Olmesartan(Combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin/Olmesartan(Combination)
Study: NCT00977938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin, Prasugrel & Aspirin
Study: NCT04175522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
Study: NCT04175457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
Study: NCT02523625

Intervention type: DEVICE
Intervention: Ultrasound of temporal and axillary arteries
Description: Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
Study: NCT03502434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

Intervention type: OTHER
Group type: OTHER
Intervention: White Petrolatum
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium lauryl sulfate
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study: NCT02022748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
Study: NCT03706937

Intervention type: OTHER
Intervention: Semi directive interview
Description: Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
Study: NCT03287843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision before 56 days (4-8 weeks)
Description: Low anterior resection or abdominoperineal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision after 56 days (8-12 weeks)
Description: Low anterior resection or abdominoperineal resection
Study: NCT03315338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, dose to be determined
Description: CORT118335 is supplied as suspension for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, dose to be determined
Description: CORT118335 is supplied as suspension for oral dosing
Study: NCT01353872

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrattente / Nutraperf / Nutrarecup
Description: 500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo
Description: 500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
Study: NCT03217123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain stimulation
Description: Electrical stimulation at subcortical level
Study: NCT03118206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction
Study: NCT02922738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VisualDx
Description: VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
Study: NCT02018575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline Lysine Amino Acid Mix
Description: Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White corn meal porridge
Description: A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
Study: NCT01038362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCEP Step 1 diet plus Almonds
Description: NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
Study: NCT03118206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study: NCT01038362

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Almonds
Description: NCEP Step 1 diet without almonds
Study: NCT02523625

Intervention type: DEVICE
Intervention: Ultrasound of temporal and axillary arteries
Description: Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries

Intervention type: DEVICE
Intervention: Ultrasound of temporal and axillary arteries
Description: Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
Study: NCT02404922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study: NCT00559806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 weeks of unilateral immobilisation and 4 weeks of resistance training
Description: 2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 weeks of unilateral immobilisation and 4 weeks of resistance training
Description: 2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
Study: NCT01453179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Study: NCT01886079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.4 mcg/kg/h, IV
Study: NCT04082156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no stimulation
Study: NCT01447277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic Block
Description: Performing a sciatic block in addition to a femoral block preoperatively

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral Block only
Description: Performing a preoperative sciatic nerve block only
Study: NCT04114487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task balance training
Description: The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task balance training
Description: The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
Study: NCT00486031

Intervention type: DRUG
Group type: OTHER
Intervention: Balsalazide Disodium
Study: NCT02458209

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bococizumab PFS:Pfizer
Description: 150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bococizumab PFS: BIP
Description: 150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bococizumab PFP
Description: 150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
Study: NCT02035358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Renal (HAR) Immunotherapy
Description: HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization.
Study: NCT04036838

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PyloPlus UBT System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology
Description: Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Urease Test
Description: Biopsy specimen obtained and placed onto Rapid Urease Test
Study: NCT02404922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study: NCT02648022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mental health interventions and case management
Description: The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
Study: NCT02485925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™
Description: Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
Study: NCT04177420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIR-C mattress
Description: infrared-C irradiation by hot mattress with a powered heating compress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIR-C abdominal pad
Description: infrared-C irradiation by hot abdominal pad with a powered heating compress

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fake FIR-C mattress
Description: normal mattress with fake controller, custom make for placebo group

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fake FIR-C abdominal pad
Description: normal abdominal pad with fake controller, custom make for placebo group
Study: NCT02270762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest in bed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive verticalization
Study: NCT04036838

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H.pylori Culture
Description: Biopsy specimen obtained and sent to lab for culture analysis
Study: NCT06032429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments
Description: SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.